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The repair of double-stranded DNA breaks and recombination are
fundamental processes for all living cells. Double-stranded DNA
damage may be repaired by homologous recombination with an
intact homologue, by the action of recombination and by repair
proteins, which are probably present in a similar fashion in various
or ganisms of di fferent evolutionary stages (Park, 1995). Among
these proteins, Rad51, Rad52 and Rad54 play a crucial role in
human cells, contributing to the aforementioned processes.
Human Rad51 protein is a homologue of the RecA protein of
Escherichia coli, and its gene maps to chromosome 15q15.1 and
encodes a putative 339-amino acid protein. It is transcribed at high
levels in thymus, spleen, testis and ovary (Shinohara et al, 1993).
Experiments reported by Benson et al (1994) show that human
Rad51 protein binds to single and double-stranded DNA and
exhibits DNA-dependent  ATPase activity to form nucleoprotein
filaments, which have been observed under electron microscopy
following negative staining.
Human Rad52 protein is essential for DNA double-stranded
break repair and meiotic and mitotic recombination, crucial
processes for the maintenance of the genetic integrity of living
or ganisms (Park et al, 1996). Studies regarding the function of the
Rad52 protein suggest that the Rad52 protein is not required for
the initiation of recombination, but is essential for the intermediate
stage following the formation of double-strand breaks but before
the appearance of stable recombinants (Park et al, 1996).
Resistance to ionizing radiation is conferred by the Rad52 protein
to monkey cells (Park, 1995). Its gene maps to chromosomal
region 12p13.3, and encodes a 418-amino acid protein (Muris et
al, 1994).
Human Rad54 protein belongs to a superfamily of DNA heli-
cases that unwind duplex DNA, forming single-stranded DNA,
thus making them available for replication, recombination and
repair (Mats   r -Rogers, 1990). Mutations in genes that
encode this protein have been found to be responsible for cance r -
prone syndromes like xeroderma pigmentosum (Sung et al, 1993)
and Bloom syndrome (Ellis et al, 1995). Its gene maps to chromo-
somal region 1p32 and encodes a 747-amino acid protein (Rasio
et al, 1997). Northern blot analysis revealed that Rad54 was
expressed in testis and thymus, and in low levels in small intestine,
colonic mucosa, breast and prostate (Rasio et al, 1997).
The DNA double-strand break repair pathway in mammalian
cells in accomplished by multiprotein complexes. That means that
specific interaction among these proteins is a reliable fact; thus,
specific interaction between Rad51 and Rad52 has been
demonstrated, suggesting that Rad52 may modulate the catalytic
activities of Rad51 protein, this interaction being species-specific
(Shinohara et al, 1993; Shen et al, 1996). Evidence of specific
protein–protein association between p53 and human Rad51
protein has been reported (Stürzbecher et al, 1996). More recentl y,
it has been established that BRCA2 and p53 proteins exist in vivo
in the same complexes, and that functional interaction between
BRCA2 and p53 is a fact, demonstrated by evidence that BRCA2
inhibits p53 transcriptional activity in cancer cells; in this wa y, the
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Avd. de la Reina  Victoria 21, 28003-Madrid, Spaincoexpression of Rad51 enhances BRCA2’s inhibitory effects
(Marmorstein et al, 1998).
An aspect that has originated a great deal of interest is the inter-
action between BRCA1/BRCA2 and Rad51 proteins. The func-
tions of BRCA1 and BRCA2 have not been completely defined,
but there is evidence to support their involvement in transcrip-
tional regulation (Chapman and Verma, 1996; Milner et al, 1997)
and in DNA repair functions (Scully et al, 1997; Sharan et al,
1997). At least in the mouse, they are required for embryonic
development (Ludwig et al, 1997; Suzuki et al, 1997), and BRCA1
has also been reported to transactivate the expression of the cyclin-
dependent kinase inhibitor p21WAF1/CIP1 in a p53-independent
manner, inhibiting cell-cycle progression into the S phase
(Somasundaram et al, 1997). However, although mutational
studies have linked BRCA1 and BRCA2 genes with hereditary
breast and ovarian cancer, their aetiopathogenic mechanisms have
not been clearly demonstrated in nullizygous mice (Connor et al,
1997; Ludwig et al, 1997; Suzuki et al, 1997).
Interaction between Rad51 and BRCA1 has been demonstrated
through co-immunoprecipitate assays showing that the two
proteins are located together in the cell nucleus in both ordinary
cells and in cells undergoing meiosis (Scully et al, 1997).
Conceivably, then, mutations in their genes could lead to cancer by
allowing cells to accumulate potentially dangerous mutations. In
the same way, Rad51 interacts with BRCA2, and coexpression of
the two genes has been shown in mouse embryos (Sharan et al,
1997), suggesting that structural alteration of either gene could
alter the integrity of the DNA repair mechanism.
Mutations in Rad51, Rad52 and Rad54 genes in human tumours
have not been reported, but a high rate of loss of heterozygosity
(LOH) in the chromosomal region of Rad54 (1p32) was observed
in breast cancer (Rasio et al, 1997). We postulated that, in sporadic
breast cancer, allelic losses in the chromosomal regions of
RAD51, RAD52, RAD54, BRCA1 and BRCA2 genes could be
notoriously found, as well as, combined losses of several regions
in the same tumours. At the same time, the relation of these mole-
cular alterations with clinicopathologic features of the patients has
been investigated.
METHODS
Tumour samples and DNA extraction
During the period from January 1997 through May 1998, 127
tumours and corresponding normal tissues were snap-frozen in
liquid nitrogen immediately after resection. All specimens under-
went histological examination by two pathologists to: (a) confirm
the diagnosis of adenocarcinoma; (b) confirm the presence of
tumour and evaluate the percentage of tumour cells comprising
these samples; and (c) carry out the pathological staging. All
samples showed at least 75% of tumour cells. To ascertain if con-
tamination with normal cells in our tumour samples may influence
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Table 1 Relationship between LOH in the BRCA1, BRCA2, RAD51, RAD52 and RAD54 regions and age and pathologic parameters in breast carcinomas
Characteristics BRCA1 BRCA2 RAD51 RAD52 RAD54
N I LOH (%) P I LOH (%) P I LOH (%) P I LOH (%) P I LOH (%) P
Tumours 127 107 53 (49) 108 47 (44) 98 31 (32) 90 14 (16) 109 22 (20)
Histologic types
IDC 107 96 50 (94) NS 97 42 (89) NS 85 28 (90) NS 75 12 (86) NS 91 19 (86) NS
Miscellaneous 20 11 3 (6) 11 5 (11) 13 3 (10) 15 2 (14) 18 3 (13)
Age
≤50 50 39 27 (51) 0.002 39 23 (49) 0.01 38 15 (48) NS 37 7 (50) NS 42 12 (55) NS
>50 77 68 26 (49) 69 24 (51) 60 16 (52) 53 7 (50) 67 10 (45)
Tumour size
≤3 cm 94 81 37 (70) NS 87 35 (74) NS 74 21 (68) NS 67 11 (79) NS 82 17 (77) NS
>3 cm 33 26 16 (30) 21 12 (26) 24 10 (32) 23 3 (21) 27 5 (23)
Lymph node metastases
≤3 104 85 34 (64) 0.0001 81 24 (51) <0.0001 77 24 (77) NS 73 11 (79) NS 88 16 (73) NS
>3 23 22 19 (36) 27 23 (49) 21 7 (23) 17 3 (21) 21 6 (27)
Oestrogen receptors
Positive 88 74 30 (57) 0.005 71 18 (38) <0.0001 65 16 (52) 0.03 61 8 (57) NS 77 13 (59) NS
Negative 39 33 23 (43) 37 29 (62) 33 15 (48) 29 6 (43) 32 9 (41)
Progesterone receptors
Positive 68 57 17 (32) <0.0001 58 16 (34) 0.0003 48 8 (26) 0.001 49 4 (29) 0.03 59 8 (36) NS
Negative 59 50 36 (68) 50 31 (66) 50 23 (74) 41 10 (71) 50 14 (64)
Histologic grade
I 27 26 6 (11) <0.0001 27 3 (6) 0.0004 17 3 (9) 0.005 16 2 (14) NS 24 0 (0) 0.02
II 53 42 17 (32) 41 21 (45) 41 8 (26) 38 4 (29) 40 9 (41)
III 47 39 30 (57) 40 23 (49) 40 20 (65) 36 8 (57) 45 13 (59)
Stage
I 27 20 4 (8) 0.01 24 2 (4) 0.0003 19 2 (6) 0.05 17 2 (14) NS 22 0 (0) 0.02
II 87 76 44 (83) 78 42 (89) 70 27 (88) 64 11 (79) 76 18 (82)
III 13 11 5 (9) 6 3 (7) 9 2 (6) 9 1 (7) 11 4 (18)
Peritumoural vessel involvement
Yes 61 48 38 (72) <0.0001 47 32 (68) <0.0001 45 17 (55) NS 46 10 (71) NS 51 13 (59) NS
No 66 59 15 (28) 61 15 (32) 53 14 (45) 44 4 (29) 58 9 (41)
Abbreviations: IDC, invasive ductal carcinoma; N, number of tumours studied; I, informative cases for markers of the corresponding region; LOH, loss of
heterozygosity.the allelic signal intensity with respect to the value considered for
the presence of LOH, we randomly selected 20 tumour samples
among the 127 cases, and microdissection was performed,
removing from them, if present, the normal tissue. After that, DNA
was extracted from microdissected and non-microdissected paired
tumour samples, and an LOH assay was done, to assess the
possible correlation between the two sets of results. DNA was
extracted from paired normal and tumour samples using a non-
organic method (Oncor. Inc., Gaithersburg, MD, USA).
Pathological parameters analysed
The following parameters were obtained from the medical records
of the 127 patients: birth date, tumour size, lymph node metas-
tases, presence of steroid receptors (oestrogen and progesterone),
histological type, peritumoural vessel involvement, pathologic
stage and histological grade. Tumour size, axillary lymph node
metastases and stage were assessed using the TNM classification.
All tumours were graded with regard to the Bloom–Richardson
grading system that includes tubule growth pattern (high tubular
formation, 1; partial tubule growth pattern, 2; little or no tubule
formation, 3), nuclear polymorphism (uniform and regular size, 1;
moderate pleomorphism, 2; highly pleomorphic with giant
nucleus, 3) and mitotic index (<10 mitosis, 1; between 10 and 19
mitosis, 2; and >20, 3). The final grade was determined by adding
the two scores: grade 1, 3–5; grade 2, 6–7; grade 3, 8–9. Presence
of peritumoural vessel invasion was analysed, and the steroid
receptor content (oestrogen and progesterone) was determined by
an immunohistochemical procedure, the results of which were
considered to be positive when 25% or more of the cells stained
positively.
PCR conditions, primers and LOH assay
Polymerase chain reaction (PCR) was performed in 25-ml volumes
using 0.2 units of Taq DNA polymerase and 1 ´ PCR buffer
(Promega, Madison, WI, USA), 200 mM dNTP, 30 pmol of each
primer and different concentrations of potassium chloride and
magnesium chloride depending on the polymorphic marker. A 30-
cycle amplification was done in a thermal cycler (Perkin-Elmer,
Cetus, Foster City, CA, USA). Three microsatellite markers were
used to determine LOH in the 15q15.1 region in tumour and
normal tissue, D15S118, D15S214 and D15S1006 (Source: J
Weissenbach, Genethon, Whitehead Institute Center for Genome
Research). In the RAD52 (12p13.3) region another three polymor-
phic markers were used to study allelic loss, D12S98, D12S1698
and D12S358 (Source: J Weissenbach, Genethon, Whitehead
Institute Center for Genome Research). The LOH study was
performed in the 1p32 region using three microsatellite markers,
D1S209, D1S411 and D1S207 (Source: J Weissenbach, Genethon,
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Table 2 Relationship between breast carcinomas with LOH in one or more of the five regions studied and tumours without LOH at any region with respect to
age and pathologic parameters
Characteristics With LOH (%) Without LOH (%) P
Tumours 70a 16b
Histologic types
IDC 62 (88.5) 14 (87.5) NS
Miscellaneous 8 (11.5) 2 (12.5)
Age
≤50 34 (48.5) 2 (12.5) 0.008
>50 36 (51.5) 14 (87.5)
Tumour size
≤3 cm 51 (73) 14 (87.5) NS
>3 cm 19 (27) 2 (12.5)
Lymph node metastases
≤3 51 (73) 15 (94) NS
>3 19 (27) 1 (6)
Oestrogen receptors
Positive 42 (60) 14 (87.5) 0.03
Negative 28 (40) 2 (12.5)
Progesterone receptors
Positive 28 (40) 13 (81) 0.003
Negative 42 (60) 3 (19)
Histologic grade
I 9 (12.9) 8 (50) 0.001
II 26 (37.1) 6 (37.5)
III 35 (50) 2 (12.5)
Stage
I 7 (10) 7 (44) 0.004
II 56 (80) 8 (50)
III 7 (10) 1 (6)
Peritumoural vessel involvement
Yes 43 (61.4) 1 (6) <0.0001
No 27 (38.6) 15 (94)
Abbreviations: IDC, invasive ductal carcinoma; LOH, loss of heterozygosity. aInformative cases for at least one marker of one region and presence of LOH in it.
bInformative cases for at least one marker in all regions studied and no presence of LOH in any of them.Whitehead Institute Center for Genome Research). Four polymor-
phic markers of the 17q21 region were used, D17S856, D17S855,
D17S1323 and D17S1327 (provided by D Goldgar, University of
Utah Medical Center, Salt Lake City, UT, USA); another four
polymorphic markers were used to study allelic loss in the BRCA2
region, D13S290, D13S260, D13S310 and D13S267 (provided by
Fergus J Couch, University of Pennsylvania, Philadelphia, PA,
USA), (Figure 1). The annealing temperatures were 55°C for the
first nine microsatellites, and 60°C, 58°C, 51°C, 60°C, 55°C,
50°C, 56°C, and 55°C respectively. The alleles were separated by
mixing 25 ml of the PCR products with a 10-ml volume of loading
buffer (total volume 35 ml), 0.02% xylene cyanol and 0.02%
bromophenol blue. Electrophoresis was run on non-denaturing
8–12% polyacrylamide gels for 12–15 h at 500 V. After gel
electrophoresis, the allelic band intensity was detected by a non-
radioisotopic technique using a commercially available silver
staining method (Oto et al, 1993).
Analysis of LOH
We analysed the allele intensities by densitometry. The gel image
was captured using a GS-690 Imaging Densitometer (Bio-Rad
Laboratories, Hercules, CA, USA), digitized in 400 dpi, and
analysed using Multi-Analyst/PC (Bio-Rad Laboratories, Hercules,
CA, USA). An allele was considered to be lost when its signal was
reduced by more than 50% with respect to that observed on the
normal counterpart DNA (Figure 2). Among the 20 cases studied
after microdissection, there were no evaluable decreases in allelic
signal intensity to below our cut-off point, 50%. Nearly all the
samples maintained a range of signal intensity similar to that exhib-
ited prior to microdissection; there was only one case, that had
shown LOH previously, in which the loss of signal intensity
changed from 50% to 75%.
Statistical analysis
The variables analysed were contrasted by means of the c2 test
with the Yates correction or Fisher’s exact test when any of the
expected frequencies were less than 5. One-tailed P-values of
< 0.05 were considered statistically significant. Statistical analyses
were performed using the EPI-INFO package, version 6.04. The
significance, observed for some of the parameters studied in
tumours with LOH and tumours without LOH, always related the
worst prognosis to tumours with allelic lost. Thus, the incidences
of age under 50 years, more than three axillary lymph node metas-
tases, negative steroid receptors, higher histological grade, higher
pathologic stage and peritumoural vessel involvement were statis-
tically significant in tumours with LOH.
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Figure 1 Illustration of the five chromosomes that harbour the regions studied, as well as, the locations and order of the microsatellite markers used, chosen
from the middle or intragenic, if available, and centromeric and telomeric positions in each region. Distances between loci are indicated in centimorgansRESULTS
LOH in the chromosomal regions of the RAD51, RAD52
and RAD54 genes
The 127 eligible breast tumours were analysed for LOH in the
regions 15q15.1, 12p13.3 and 1p32, that harbour RAD51, RAD52
and RAD54 genes respectively. Patient age and the pathologic
parameters analysed in this study are shown in Table 1. Allelic loss
was observed for at least one marker in 31 (32%) of the 98 cases
that were informative for microsatellite of the 15q15.1 region; in
14 (16%) of the 90 cases informative for the 12p13.3 region; and
22 (20%) of the 109 cases informative for 1p32 region. When we
compared the aforementioned pathological features of the tumours
with presence or absence of LOH in the three regions studied, the
following parameters showed statistically significant differences:
for the RAD51 region, oestrogen receptor content, progesterone
receptors, higher grade and higher stage; for the RAD52 region,
progesterone receptor content; and for the RAD54 region, higher
grade and higher stage. The statistically significant P-values for
these parameters are shown in Table 1.
LOH in the 17q21 and 13q12 regions
The same 127 eligible cases were also studied for LOH in the
BRCA1 and BRCA2 regions. Patient ages and the pathologic
parameters analysed in this study are shown in Table 1. LOH was
found for at least one marker in the BRCA1 region in 53 (49%) of
107 cases that were informative for this region. When LOH was
studied in the 13q12 region, allelic loss was observed for at least
one marker in 47 (44%) of 108 cases that resulted informative for
this region. When LOH in these two regions was correlated with
age and pathologic findings, we observed statistically significant
differences between tumours with and without LOH with respect
to the following parameters: age, grouping the patients depending
on whether they were older or younger than 50 years, lymph node
metastases, oestrogen receptor content, progesterone receptors,
higher grade, higher stage and peritumoural vessel involvement.
Again, the statistically significant P-values for the BRCA1 and
BRCA2 regions may be observed in Table 1.
Pathologic correlations between tumours with LOH and
tumours without LOH
When we considered the cases with LOH in one or more of the five
regions studied, and compared them with the tumours without
LOH in any regions with respect to patient age and histopatho-
logical parameters, we found that six parameters were statistically
significant: age over or under 50 years (P= 0.008), oestrogen
receptor content (P= 0.03), progesterone receptors (P= 0.003),
higher grade (P= 0.001), higher stage (P= 0.004) and peri-
tumoural vessel involvement (P< 0.0001); but there was no corre-
lation with regard to histological type, tumour size or lymph node
metastases (Table 2). It is noteworthy that the three patients with
LOH in all five regions studied were under 30 years of age and
showed more than eight affected axillary lymph nodes, negative
steroid receptors, histological grade III and presence of peri-
tumoural vessel invasion.
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Table 3   Analysis of differences between cases expected with LOH in two or more regions concomitantly and the real cases observed with LOH in the same
regions
Regions
studied together BRCA1 BRCA2 RAD51 RAD52 RAD54 F I E O
+ + 0.215 90 19 25
+ + 0.15 84 13 24
+ + 0.076 75 6 10
+ + 0.098 92 9 17
2 + + 0.136 80 11 12
+ + 0.067 77 5 6
+ + 0.088 91 8 12
+ + 0.05 74 4 9
+ + 0.063 89 6 11
+ + 0.03 82 2 3
+ + + 0.068 80 5 9
+ + + 0.033 66 2 4
+ + + 0.043 75 3 7
+ + + 0.023 62 1 7
3 + + + 0.03 71 2 10
+ + + 0.015 64 1 3
+ + + 0.021 60 1 6
+ + + 0.027 82 2 4
+ + + 0.013 64 1 3
+ + + 0.01 66 1 3
+ + + + 0.01 51 1 3
+ + + + 0.013 62 1 4
4 + + + + 0.0063 57 0 3
+ + + + 0.0045 49 0 3
+ + + + 0.004 51 0 3
5 + + + + + 0.002 44 0 3
F, probability of LOH at different regions considered simultaneously; I, number of informative cases for the regions studied concomitantly; E, expected LOH
cases for each combination of regions; O, real cases observed with LOH in all regions analysed; +, in horizontal, regions examined in unison.Analysis of the observed versus expected frequency of
concomitant LOH in several regions
We examined the real rate of cases with LOH in two, three, four
and five regions simultaneously and compared them with their
expected frequency (statistical probability) calculated on the basis
of the LOH rate of each region and the number of informative
cases for the same region. Briefly, we determined the expected
frequency of LOH in BRCA1 and BRCA2 regions together,
through the product of the rate of LOH in BRCA1 (49%) and that
of LOH in BRCA2 (44%) and by the informative cases for both
regions (n = 90), resulting in 19 cases (Table 3). All associations
among regions showed more cases observed than expected on the
basis of their individual LOH rates; moreover, the proportions
between cases expected and observed increased in parallel with
the simultaneous regions considered, these being greater if we
considered LOH concomitantly in four or five regions rather than
in two regions (Table 3).
DISCUSSION
The functional effect of the loss of one allele of a specific gene,
like that analysed in this study, is hypothetical because the loss of
the gene function will depend on the inactivation of the other allele
by homozygous deletion, promoter methylation or point mutation
and, to date, no evidence of somatic RAD51, RAD52, RAD54 or
BRCA1 gene mutations has been reported in breast tumours, and
they have been detected only exceptionally in the BRCA2 gene
(Lancaster et al, 1996; Miki et al, 1996; Teng et al, 1996).
However, the identification of chromosomal regions with allelic
losses is a useful method for screening genes implicated in the
pathogenesis of human malignant tumours, and, at the same time,
offers the opportunity to investigate new parameters with possibly
high sensitivity and specificity for use as prognostic factors.
In breast cancer, high rates of LOH involving several polymor-
phic markers in the chromosomal regions of BRCA1, BRCA2 and
RAD54 have been detected by other authors (Cleton-Jansen et al,
1995; Beckmann et al, 1996; van der Berg et al, 1996; Rasio et al,
1997) who reported incidences very similar to those observed in
this study, but no evidence of LOH in regions of RAD51 and
RAD52 genes has been documented. The significant rate of LOH
in regions of RAD51 and RAD52 genes here reported, mainly for
the RAD51 gene (15q15.1), may indicate that the genes of these
regions, not only RAD51 and RAD52, can play a role in the devel-
opment of breast cancer and in determining the pathologic features
of the tumours. Evidence that allelic loss in the BRCA1 and
BRCA2 regions is of prognostic value resulted from the compar-
ison of this molecular alteration with pathologic parameters of the
tumours (Beckmann et al, 1996; van der Berg et al, 1996), with
findings similar to those observed in our series (Table 1).
However, no studies are available to contrast our results indicating
the significant relation of LOH in RAD51, RAD52 and RAD54
regions with several pathologic parameters, usually accepted as
associated with poor prognosis. From the overall point of view,
analysing all the cases with LOH in one or more regions concomi-
tantly and the tumours with no allelic loss, the statistically signifi-
cant differences observed in the individual analysis persisted
except in the case of age and lymph node metastases (Table 2).
These data suggest that the genes of these regions may influence
the specific pathological phenotype of breast carcinomas, either
single or combined, because they may perform common or syner-
gistic functions in the control and progression of tumour cells,
participating in these processes through the repair of double-
stranded DNA and normal chromosomal recombination mecha-
nisms, like those previously reported for BRCA1 and RAD51
(Scully et al, 1997), BRCA2 and RAD51 (Sharan et al, 1997),
RAD51 and RAD52 (Shen et al, 1996) or others undetermined.
It is widely accepted that the clinical behaviour of a tumour will
be conditioned by its intrinsic biological features (Harris et al,
1997); in this context, LOH of some chromosomal regions, like
those here analysed, could also be a molecular factor related to
high-grade malignancy, and its determination may help to identify
subgroups of patients with a poor prognosis, and eventually to
develop more specific treatment strategies.
In breast carcinomas, extensive studies have found many chro-
mosomal regions deleted throughout the genome, suggesting that
several putative tumour suppressor genes could be implicated in
their pathogenesis, although the number and the relevance of each
is currently unknown (Devilee and Cornelisse, 1994; Bièche and
Lidereau, 1995; Kerangueven et al, 1997; Phelan et al, 1998).
Allelic loss is a genetic alteration that indirectly may indicate the
presence of tumour suppressor gene, a phenomenon that apparently
can be multiple and originates during tumour progression (Devilee
and Cornelisse, 1994; Bièche and Lidereau, 1995). On the basis of
this presumption and the aforementioned similar functions of some
genes of the chromosomal regions here studied, we analysed
whether the rates of concomitant LOH in two or more regions were
parallel to its statistical probability, or showed deviations. The
cases observed in our series were always higher than expected for
the association of the regions considered. The difference expected
508 R Gonzalez et al
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Figure 2 Photographs of gels, taken under normal light after staining with a
(NO3)Ag method, showing examples of loss of heterozygosity at some of the
different loci studied in the 15q15.1, 12p13.3, 1p32, 17q21 and 13q12–13
regions. N, normal tissue; T, tumour; <, allelic loss in tumour DNAand observed between cases increased in a manner that approxi-
mated the number of regions with LOH taken together (Table 3).
These facts suggest that the presence of two or more regions with
deletions in breast carcinomas is not a random event and that it
could be related to the development of these malignancies,
contributing to their definite pathological phenotype.
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